| Date |
Title |
|
|
August 4, 2022
|
Fulgent Genetics Reports Second Quarter 2022 Financial Results
|
|
|
August 4, 2022
|
Fulgent Genetics Announces Launch of PCR Based Test to Detect Monkeypox
|
|
|
August 4, 2022
|
Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors
|
|
|
July 19, 2022
|
Fulgent Genetics to Announce Second Quarter 2022 Financial Results on Thursday, August 4, 2022
|
|
|
July 5, 2022
|
The American Medical Association Approves a New Category I CPT® Code for the HelioLiver™ Test
|
|
|
May 3, 2022
|
Fulgent Genetics Announces Promotions and Leadership Updates
|
|
|
May 3, 2022
|
Fulgent Genetics Reports First Quarter 2022 Financial Results
|
|
|
May 3, 2022
|
Fulgent Genetics Announces Opening of New State-of-the-Art Oncology Laboratory in El Monte, California
|
|
|
April 18, 2022
|
Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results
|
|
|
April 18, 2022
|
Fulgent Genetics to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022
|
|
|
March 8, 2022
|
Fulgent Genetics Announces $250 Million Share Repurchase Program
|
|
|
March 8, 2022
|
Representatives of Fulgent Genetics to Participate in Oppenheimer’s 32nd Annual Healthcare Conference
|
|
|
February 23, 2022
|
Fulgent Genetics Announces Strategic Investment in Spatial Genomics
|
|
|
February 23, 2022
|
Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results
|
|
|
February 14, 2022
|
Fulgent Genetics to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday February 23, 2022
|
|
